Understanding how epigenetics affects autoantibody responses in lupus
Epigenetics of the autoantibody response in systemic lupus
This study is looking at how certain genes and proteins affect the way B cells make antibodies in people with lupus, to better understand why some of these antibodies mistakenly attack the body instead of helping it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-10903794 on NIH RePORTER |
What this research studies
This research investigates the role of epigenetic factors in the autoantibody response associated with systemic lupus. It focuses on how B cells undergo processes like class-switch recombination and somatic hypermutation, which are essential for producing effective antibodies. By examining the influence of specific genes and proteins, such as AID and Blimp-1, the study aims to uncover how these factors contribute to the development of autoantibodies in lupus patients. The research employs advanced techniques like ATAC sequencing to analyze the epigenetic landscape of B cells in lupus.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with systemic lupus who exhibit autoantibody responses.
Not a fit: Patients without a diagnosis of systemic lupus or those who do not produce autoantibodies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for managing systemic lupus by targeting the underlying epigenetic mechanisms.
How similar studies have performed: Other research has shown promising results in understanding the role of epigenetics in autoimmune diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Casali, Paolo — University of Texas Hlth Science Center
- Study coordinator: Casali, Paolo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.